Skip to content

Psychedelic-assisted therapy: all studies

Page 236 of 294: studies 2,351 to 2,360 of 2,939, newest first. Back to the psychedelic-assisted therapy overview

Research

A unified model of ketamine's dissociative and psychedelic properties.

Journal of Psychopharmacology December 17, 2022 Miriam Marguilho, Inês Figueiredo, Pedro Castro-Rodrigues 57 citations

Ketamine is an N-methyl-d-aspartate antagonist which is increasingly being researched and used as a treatment for depression. In low doses, it can cause a transitory modification in consciousness which was classically labelled as ‘dissociation’. However, ketamine is also commonly classified as an atypical psychedelic and it has been recently reported that ego dissolution experiences during...

DOI: 10.1177/02698811221140011 (opens in new tab) Full text (opens in new tab) Psychopharmacology Mental health Consciousness research Ketamine therapy

Application of machine learning and complex network measures to an EEG dataset from ayahuasca experiments

PLoS One December 16, 2022 Caroline L. Alves, Rubens Gisbert Cury, Kirstin Roster et al. 13 citations

Ayahuasca is a blend of Amazonian plants that has been used for traditional medicine by the inhabitants of this region for hundreds of years. Furthermore, this plant has been demonstrated to be a viable therapy for a variety of neurological and mental diseases. EEG experiments have found specific brain regions that changed significantly due to ayahuasca. Here, we used an EEG dataset to...

DOI: 10.1371/journal.pone.0277257 (opens in new tab) Ayahuasca Electroencephalography Dementia Artificial intelligence +6

Pharmacological Mechanism of the Non-hallucinogenic 5-HT2A Agonist Ariadne and Analogs

ACS Chemical Neuroscience December 15, 2022 Michael J. Cunningham, Hailey A. Bock, Inis C. Serrano et al. 65 citations

Ariadne is a non-hallucinogenic analog in the phenylalkylamine chemical class of psychedelics that is closely related to an established synthetic hallucinogen, 2,5-dimethoxy-4-methyl-amphetamine (DOM), differing only by one methylene group in the α-position to the amine. Ariadne has been tested in humans including clinical trials at Bristol-Myers Company that indicate a lack of hallucinogenic...

Therapeutic uses of psychedelics for eating disorders and body dysmorphic disorder

Journal of Psychopharmacology December 14, 2022 Nicole Ledwos, Justyne D. Rodas, Muhammad Ishrat Husain et al. 20 citations

BACKGROUND: Clinical use of psychedelics has gained considerable attention, with promising benefits across a range of mental disorders. Current pharmacological and psychotherapeutic treatments for body dysmorphic disorder (BDD) and eating disorders (EDs) have limited efficacy. As such, other treatment options such as psychedelic-assisted therapies are being explored in these clinical groups....

DOI: 10.1177/02698811221140009 (opens in new tab) Full text (opens in new tab) Body dysmorphic disorder Eating disorders Clinical psychology Medline +1

History of epilepsy increases risk of psychedelic‐induced seizures

The Brown University Psychopharmacology Update December 10, 2022

Classic psychedelic drugs such as psilocybin have been associated with reduced depressive symptoms when used as an adjunct to therapy, but concern remains over the potential for adverse events such as seizures when these drugs are used outside controlled clinical settings. A study used a survey of U.S. adults to examine the association between use of classic psychedelics and seizures. The...

Moderators of ayahuasca’s biological antidepressant action

Frontiers in Psychiatry December 5, 2022 Geovan Menezes de Sousa, Vagner Deuel de Oliveira Tavares, Ana Cecília de Menezes Galvão et al. 14 citations

Introduction The understanding of biological responses to psychedelics with antidepressant potential is imperative. Here we report how a set of acute parameters, namely emotional (depressive symptoms), cognitive (psychedelic experience), and physiological (salivary cortisol), recorded during an ayahuasca dosing session, modulated serum brain-derived neurotrophic factor (BDNF), serum cortisol...

DOI: 10.3389/fpsyt.2022.1033816 (opens in new tab) Cortisol Inflammation Psychedelics hallucinogens Entheogens +7

The economics of psychedelic-assisted therapies: A research agenda

Frontiers in Psychiatry December 5, 2022 Elliot Marseille, Stefano Bertozzi, James G. Kahn 51 citations

After a long hiatus, psychiatry is undergoing a resurgence of interest in psychedelic drugs as therapy for a wide range of mental health disorders Accumulating clinical evidence suggests substantial potential for psychedelics used in a therapeutic context, as treatment for, among other disorders, depression, post-traumatic stress disorder (PTSD), and addictions to tobacco, opioids and alcohol....

DOI: 10.3389/fpsyt.2022.1025726 (opens in new tab) MDMA Psilocybin Cost-effectiveness Health economics +5

Lower-dose psycholytic therapy – A neglected approach

Frontiers in Psychiatry December 2, 2022 Torsten Passie, Jeffrey Guss, Rainer Krähenmann 71 citations

Lysergic acid diethylamide (LSD) and similar psychoactive drugs have been used in psychotherapy since 1949, when the first clinical study with lower-dose LSD showed therapeutically relevant effects. This caused an intense interest among psychotherapists and researchers, alike, on an international scale. In 1960, the use of serial lower-dose LSD/psilocybin sessions in a psychoanalytical...

Patients' recovery and non-recovery narratives after intravenous ketamine for treatment-resistant depression.

Journal of Affective Disorders December 1, 2022 Adrienne Lapidos, Daniela Lopez-Vives, Cortney E. Sera et al.

BACKGROUND Intravenous (IV) ketamine is an effective therapy for treatment-resistant depression. A large data base is confirmatory and steadily expanding. Qualitative studies can inform best practices and suggest new research directions. As part of a clinical trial designed to identify biomarkers of ketamine response, a qualitative study was conducted to characterize experiences with: receiving...

(De)criminalisation of psychedelics in the Czech Republic-Where are we heading in drug policy and legislation?

International Journal of Drug Policy December 2022 Tereza Dleštíková

The article deals with the issue of decriminalization of drugs, in all relevant contexts, both in terms of criminal policy and legislation, as well as law enforcement, with focus on the Czech Republic. The article proceeds deductively from the general to the specific. First, it discusses the role of law in society and its legitimacy, with focus on legitimate criminal sanctions, which are...

DOI: 10.1016/j.drugpo.2022.103900 (opens in new tab) Full text (opens in new tab) Czech republic Decriminalization Drug policy Law and society +2